Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2024 08:00 ET | Source: Oculis Holding AG

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
July 30, 2024 16:10 ET | Source: Oculis Holding AG

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
June 27, 2024 06:30 ET | Source: Oculis Holding AG

Oculis and EURETINA Announces the Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and...
June 10, 2024 05:00 ET | Source: Oculis Holding AG

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1 genetic biomarker population as identified in prior...
June 10, 2024 05:00 ET | Source: Oculis Holding AG

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Improvements in multiple sign efficacy endpoints were observed in full population and with predictive and more pronounced effects in the TNFR1...
June 10, 2024 05:00 ET | Source: Oculis Holding AG

Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð

ZUG, Sviss, June 10, 2024 (GLOBE NEWSWIRE) -- Virkni lyfsins var greinileg með bætingu á mörgum teiknum (e. signs) augnþurrks í öllum rannsóknarhópnum ásamt því sem aukin áhrif sáust hjá hópi...
June 04, 2024 13:47 ET | Source: Oculis Holding AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity...
May 30, 2024 04:00 ET | Source: Oculis Holding AG

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) --Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS...
May 30, 2024 04:00 ET | Source: Oculis Holding AG

Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð

ZUG, Sviss, May 30, 2024 (GLOBE NEWSWIRE) -- Hluthafar samþykktu alla dagskrárliði og tillögur stjórnarRobert K. Warner M.B.A. og Arshad M. Khanani M.D. M.A. FASRS kjörnir í stjórnBaruch D....
May 30, 2024 04:00 ET | Source: Oculis Holding AG

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D....